Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 328,225
  • Shares Outstanding, K 181,340
  • Annual Sales, $ 31,430 K
  • Annual Income, $ -292,070 K
  • 60-Month Beta 3.20
  • Price/Sales 10.79
  • Price/Cash Flow N/A
  • Price/Book 9.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.24
  • Number of Estimates 1
  • High Estimate -0.24
  • Low Estimate -0.24
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5500 +16.77%
on 03/18/20
2.4800 -27.02%
on 03/06/20
-0.3700 (-16.97%)
since 02/27/20
3-Month
1.5500 +16.77%
on 03/18/20
5.0900 -64.44%
on 01/10/20
-1.5500 (-46.13%)
since 12/27/19
52-Week
1.3900 +30.22%
on 10/11/19
5.0900 -64.44%
on 01/10/20
-2.9000 (-61.57%)
since 03/27/19

Most Recent Stories

More News
Sorrento Launches Novel I-Cell(TM) COVID-19 Cellular Vaccine Program

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA's Center for...

SRNE : 1.8100 (-3.21%)
SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB(TM) TO POTENTIALLY TREAT COVID-19

-- ACE-MAB is in the cGMP cell line development stage by our strategic partner, Mabpharm Limited, and could be ready for large-scale production in Mabpharm's 30,000 m cGMP facilities in China for human...

SRNE : 1.8100 (-3.21%)
Company News for Mar 23, 2020

Companies In The News Are: BLPH, GNMK, WORK, SRNE

GNMK : 4.16 (+1.22%)
BLPH : 12.67 (+11.43%)
SRNE : 1.8100 (-3.21%)
WORK : 28.58 (+0.35%)
SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19

In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and SmartPharm Therapeutics Inc. (SmartPharm) today announced a research...

SRNE : 1.8100 (-3.21%)
Biotechs and Big Pharma in a Race Against Time Battling Global Health Crisis

In the months since the global public health crisis rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. The...

CNSP : 2.12 (-11.30%)
WBIO.CN : 0.740 (-2.63%)
SRNE : 1.8100 (-3.21%)
MRNA : 30.05 (+7.55%)
GILD : 72.85 (-1.37%)
INO : 8.32 (+16.36%)
SORRENTO DEVELOPS STI-4398 (COVIDTRAP(TM) PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)

-- COVIDTRAP is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;

SRNE : 1.8100 (-3.21%)
Earnings Preview: Sorrento Therapeutics (SRNE) Q4 Earnings Expected to Decline

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SRNE : 1.8100 (-3.21%)
Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?

Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.

SRNE : 1.8100 (-3.21%)
ServiceSource Announces Four New Appointments to Board of Directors

ServiceSource (NASDAQ: SREV), the digital customer journey experience company, announced today the appointment of Andrew (Andy) M. Baker, Jane Okun Bomba, John A. Meyer, and Robin L. Smith to the Company's...

INFO : 59.05 (-0.86%)
BV : 10.81 (-4.00%)
ACXM : 48.48 (-1.88%)
ALU : 3.46 (+0.87%)
SRNE : 1.8100 (-3.21%)
SEEL : 0.5000 (-5.66%)
RMTI : 2.19 (-10.61%)
SGNL : 12.30 (-15.17%)
SREV : 0.9249 (+5.10%)
Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial

-- Fourteen subjects with advanced cancer pain received epidural RTX (04 to 15 ug)

SRNE : 1.8100 (-3.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade SRNE with:

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

2nd Resistance Point 1.9567
1st Resistance Point 1.8833
Last Price 1.8100
1st Support Level 1.7433
2nd Support Level 1.6767

See More

52-Week High 5.0900
Fibonacci 61.8% 3.6766
Fibonacci 50% 3.2400
Fibonacci 38.2% 2.8034
Last Price 1.8100
52-Week Low 1.3900

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar